These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 17724444)

  • 1. Evaluation of intervention strategy based on CMV-specific immune responses after allogeneic SCT.
    Avetisyan G; Aschan J; Hägglund H; Ringdén O; Ljungman P
    Bone Marrow Transplant; 2007 Nov; 40(9):865-9. PubMed ID: 17724444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation.
    Avetisyan G; Larsson K; Aschan J; Nilsson C; Hassan M; Ljungman P
    Bone Marrow Transplant; 2006 Nov; 38(10):687-92. PubMed ID: 17001346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-transplant cytomegalovirus (CMV) serostatus remains the most important determinant of CMV reactivation after allogeneic hematopoietic stem cell transplantation in the era of surveillance and preemptive therapy.
    George B; Pati N; Gilroy N; Ratnamohan M; Huang G; Kerridge I; Hertzberg M; Gottlieb D; Bradstock K
    Transpl Infect Dis; 2010 Aug; 12(4):322-9. PubMed ID: 20487414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation may identify patients at risk for recurrent CMV reactivations.
    Gratama JW; Brooimans RA; van der Holt B; Sintnicolaas K; van Doornum G; Niesters HG; Löwenberg B; Cornelissen JJ
    Cytometry B Clin Cytom; 2008 Jul; 74(4):211-20. PubMed ID: 18454493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope.
    Ohnishi M; Sakurai T; Heike Y; Yamazaki R; Kanda Y; Takaue Y; Mizoguchi H; Kawakami Y
    Br J Haematol; 2005 Nov; 131(4):472-9. PubMed ID: 16281937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
    Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
    Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function.
    Nickel P; Bold G; Presber F; Biti D; Babel N; Kreutzer S; Pratschke J; Schönemann C; Kern F; Volk HD; Reinke P
    Transpl Immunol; 2009 Mar; 20(4):238-42. PubMed ID: 19032982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT.
    Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; López J; Garcia-Noblejas A; Muñoz-Cobo B; Costa E; Clari MA; Hernández-Boluda JC; Remigia MJ; Navarro D
    Bone Marrow Transplant; 2011 Nov; 46(11):1437-43. PubMed ID: 21243030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Augmentation of virus-specific immunity after hematopoietic stem cell transplantation by adoptive T-cell therapy.
    Peggs KS; Mackinnon S
    Hum Immunol; 2004 May; 65(5):550-7. PubMed ID: 15172456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus infection and disease after reduced intensity conditioning allogeneic stem cell transplantation: single-centre experience.
    Piñana JL; Martino R; Barba P; Margall N; Roig MC; Valcárcel D; Sierra J; Rabella N
    Bone Marrow Transplant; 2010 Mar; 45(3):534-42. PubMed ID: 19668235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
    Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
    Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus-specific cellular immune responses and viremia in recipients of allogeneic stem cell transplants.
    Aubert G; Hassan-Walker AF; Madrigal JA; Emery VC; Morte C; Grace S; Koh MB; Potter M; Prentice HG; Dodi IA; Travers PJ
    J Infect Dis; 2001 Oct; 184(8):955-63. PubMed ID: 11574909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reconstitution of cytomegalovirus specific T cells after pediatric allogeneic stem cell transplantation: results from a pilot study using a multi-allele CMV tetramer group.
    Koehl U; Dirkwinkel E; Koenig M; Erben S; Soerensen J; Bader P; Doerr HW; Preiser W; Weissinger E; Klingebiel T; Martin H; Lehrnbecher T
    Klin Padiatr; 2008; 220(6):348-52. PubMed ID: 18949669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human herpesvirus 6 infection and cytomegalovirus-specific lymphoproliferative responses in allogeneic stem cell transplant recipients.
    Wang FZ; Larsson K; Linde A; Ljungman P
    Bone Marrow Transplant; 2002 Oct; 30(8):521-6. PubMed ID: 12379892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the NucliSens CMV pp67 assay for detection and monitoring of human cytomegalovirus infection after allogeneic stem cell transplantation.
    Hebart H; Rudolph T; Loeffler J; Middeldorp J; Ljubicic T; Jahn G; Einsele H
    Bone Marrow Transplant; 2002 Aug; 30(3):181-7. PubMed ID: 12189537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation.
    Widmann T; Sester U; Gärtner BC; Schubert J; Pfreundschuh M; Köhler H; Sester M
    PLoS One; 2008; 3(11):e3634. PubMed ID: 18982061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
    Barron MA; Gao D; Springer KL; Patterson JA; Brunvand MW; McSweeney PA; Zeng C; Barón AE; Weinberg A
    Clin Infect Dis; 2009 Dec; 49(12):1777-83. PubMed ID: 19911937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tetramer monitoring to assess risk factors for recurrent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell transplantation.
    Borchers S; Luther S; Lips U; Hahn N; Kontsendorn J; Stadler M; Buchholz S; Diedrich H; Eder M; Koehl U; Ganser A; Mischak-Weissinger E
    Transpl Infect Dis; 2011 Jun; 13(3):222-36. PubMed ID: 21585633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
    Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
    J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.